GSK’s Arexvy Vaccine Receives the EC’s Approval for its Expanded Age Indication to Prevent Lower Respiratory Tract Disease (LRTD)
Shots:
- The EC has granted approval to Arexvy (RSV vaccine) to prevent lower respiratory tract disease (LRTD) due to respiratory syncytial virus (RSV) in adults aged 50-59yrs. It was previously approved for the same in adults aged ≥60yrs.
- The approval was based on P-III study assessing the safety & immune response of the vaccine among individuals (50-59yrs.), incl. the ones with high risk of RSV-LRTD due to underlying medical conditions
- GSK has filed for regulatory approval for the same across Japan and other regions, with their review underway. Results from studies in adults aged 18-49yrs. at increased risk and immunocompromised adults aged ≥18yrs. are anticipated in H2’24
Ref: GSK | Image: GSK
Related News:- GSK’s Arexvy Gains the US FDA’s Approval for Expanded Age Indication to Prevent RSV Lower Respiratory Tract Disease
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
